Press Release Jamison Wright 4/22/26 Press Release Jamison Wright 4/22/26 PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Read More Press Release Jamison Wright 12/5/25 Press Release Jamison Wright 12/5/25 PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Read More Publication Jamison Wright 10/1/24 Publication Jamison Wright 10/1/24 Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Read More Publication Jamison Wright 2/8/24 Publication Jamison Wright 2/8/24 Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. (Copy) Read More
Press Release Jamison Wright 4/22/26 Press Release Jamison Wright 4/22/26 PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Read More
Press Release Jamison Wright 12/5/25 Press Release Jamison Wright 12/5/25 PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Read More
Publication Jamison Wright 10/1/24 Publication Jamison Wright 10/1/24 Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Read More
Publication Jamison Wright 2/8/24 Publication Jamison Wright 2/8/24 Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. (Copy) Read More
